BG103512A - Substituted pyramidine compounds and their application - Google Patents

Substituted pyramidine compounds and their application

Info

Publication number
BG103512A
BG103512A BG103512A BG10351299A BG103512A BG 103512 A BG103512 A BG 103512A BG 103512 A BG103512 A BG 103512A BG 10351299 A BG10351299 A BG 10351299A BG 103512 A BG103512 A BG 103512A
Authority
BG
Bulgaria
Prior art keywords
application
compounds
prevention
treatment
substituted
Prior art date
Application number
BG103512A
Other languages
Bulgarian (bg)
Other versions
BG65128B1 (en
Inventor
Ulrike Spohr
Michael Malone
Nathan Mantlo
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of BG103512A publication Critical patent/BG103512A/en
Publication of BG65128B1 publication Critical patent/BG65128B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The new compounds are effective for prevention and treatment of diseases running with mediation of TNF-alpha, IL-beta, IL-6 and/or IL-8 for reducing pains and in diabetes. The invention relates to new compounds, to their analogues, promedicamentous forms and pharmaceutically acceptable salts, pharmaceutical compositions and to methods for prevention and treatment, as well as to processes for the preparation of their compounds and to intermediate products. 31 claims
BG103512A 1996-12-05 1999-06-22 Substituted pyramidine compounds and their application BG65128B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3212896P 1996-12-05 1996-12-05
US5095097P 1997-06-13 1997-06-13
US97605497A 1997-11-21 1997-11-21

Publications (2)

Publication Number Publication Date
BG103512A true BG103512A (en) 2000-07-31
BG65128B1 BG65128B1 (en) 2007-03-30

Family

ID=27364030

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103512A BG65128B1 (en) 1996-12-05 1999-06-22 Substituted pyramidine compounds and their application

Country Status (11)

Country Link
EP (1) EP0948497A2 (en)
CN (1) CN1246858A (en)
AR (1) AR048564A1 (en)
AU (1) AU733877C (en)
BG (1) BG65128B1 (en)
BR (1) BR9713850A (en)
CA (1) CA2274063C (en)
CZ (1) CZ296911B6 (en)
HU (1) HUP0001698A3 (en)
IL (1) IL130180A0 (en)
NZ (1) NZ335997A (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295026B2 (en) * 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
WO2003037888A1 (en) 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
AU2002337498B2 (en) 2001-09-21 2006-08-10 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
TWI330183B (en) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US7683069B2 (en) 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
PT2629776T (en) * 2010-10-18 2017-11-15 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
TWI651310B (en) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 Triterpenoids and their medical use
CA3002632C (en) * 2015-10-29 2023-08-29 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759176A (en) * 1969-11-20 1971-05-19 Sandoz Sa PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THESE DERIVES
US4438117A (en) * 1980-09-03 1984-03-20 E. I. Du Pont De Nemours And Company 2-Substituted thio-4,5-diarylpyrimidines
DE3319843A1 (en) * 1983-06-01 1984-12-06 Ali-Akbar Dipl.-Chem. Dr. 4300 Mülheim Pourzal Process for the preparation of pyrimidines from nitrile and alkynes
US4500533A (en) * 1983-06-22 1985-02-19 Eli Lilly And Company 2,4,5-Triaryl pyrimidines and a method of treating pain, fever, thrombosis, inflammation and arthritis
US5077142A (en) * 1989-04-20 1991-12-31 Ricoh Company, Ltd. Electroluminescent devices
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
HUP0001698A2 (en) 2001-04-28
IL130180A0 (en) 2000-06-01
BR9713850A (en) 2000-02-29
AU733877C (en) 2003-05-08
AU733877B2 (en) 2001-05-31
AU6012098A (en) 1998-06-29
CA2274063A1 (en) 1998-06-11
EP0948497A2 (en) 1999-10-13
CN1246858A (en) 2000-03-08
CZ9902015A3 (en) 1999-11-17
HUP0001698A3 (en) 2002-07-29
CZ296911B6 (en) 2006-07-12
BG65128B1 (en) 2007-03-30
AR048564A1 (en) 2006-05-10
CA2274063C (en) 2007-09-04
NZ335997A (en) 2001-08-31

Similar Documents

Publication Publication Date Title
BG103521A (en) Substituted pyrimidinon and pyridon compounds and methods for their application
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
UA49869C2 (en) NAPHTHYL-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHOD FOR TREATMENT (VARIANTS), METHOD FOR INHIBITING HUMAN FACTOR Xa OR IIa
IL136711A0 (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use
WO1998024782A3 (en) Substituted pyrimidine compounds and their use
MXPA05003302A (en) Therapeutic piperazine compounds.
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
BR9507073A (en) Composed processes to prepare the same and to treat a disease in the central nervous system pharmaceutical composition and use of the compound
MXPA04004552A (en) Substituted indolizine-like compounds and methods of use.
EP0765160A4 (en)
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
IL107134A0 (en) Pharmaceutical compositions for the treatment of parkinson's disease
PT758241E (en) USE OF CERTAIN METHANBOSPHOSPHONIC ACID DERIVATIVES TO PREVENT THE DISPOSAL OF PROTESES AND PROTEIN MIGRATION
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
BG103512A (en) Substituted pyramidine compounds and their application
DE69521536D1 (en) Compositions containing G-CSF and a TNF binding protein
MX9701820A (en) PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE.
MX9403088A (en) Indole derivatives.
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
MX9705916A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc, optionally together with azt, ddi or ddc.
DE60306503D1 (en) STATIN THERAPY FOR IMPROVING THE MAINTENANCE OF COGNITIVE FUNCTION
DE69434002D1 (en) 2,3 DIARYL-1-BENZOPYRAME FOR TREATING DERMATITIS
UA41326C2 (en) Pharmaceutical composition for prevention or treatment of viral diseases, means for prevention or treatment of viral diseases